Market-Moving News for June 20th
$ACN
$HROW
$TPST
Real Estate
Real Estate
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 1/22/2026 | $313.00 | Buy | Berenberg | |
| 1/22/2026 | $11.00 | Neutral → Buy | H.C. Wainwright | |
| 1/6/2026 | $317.00 | Buy | Truist | |
| 12/16/2025 | $320.00 | Equal-Weight → Overweight | Morgan Stanley | |
| 10/23/2025 | $266.00 | Neutral | Citigroup | |
| 10/22/2025 | $251.00 | Equal Weight | Wells Fargo | |
| 9/3/2025 | $250.00 | Buy → Neutral | Rothschild & Co Redburn | |
| 7/28/2025 | $240.00 | Reduce | HSBC Securities |
Berenberg initiated coverage of Accenture with a rating of Buy and set a new price target of $313.00
H.C. Wainwright upgraded Tempest Therapeutics from Neutral to Buy and set a new price target of $11.00
Truist initiated coverage of Accenture with a rating of Buy and set a new price target of $317.00
Accenture Federal Services, a subsidiary of Accenture (NYSE:ACN), has been selected to support the U.S. Department of Veterans Affairs (VA) Electronic Health Record Modernization (EHRM) program. This innovative 4.5-year contract marks a pivotal milestone in VA's mission to transform healthcare delivery for more than 9 million Veterans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204089246/en/ The EHRM program is a critical and strategic initiative to replace legacy systems with the modern, integrated Oracle Health Electronic Health Record (EHR) system. This transition is designed to create a single, seamless, and secure li
All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in China planned for 2027Operational runway extended to mid-2027, supporting multiple potential value-generating milestonesMatt Angel, Ph.D., joins Tempest as President and CEOPreviously announced transaction closed following stockholder approval of share issuance at the 2025 Annual Meeting on January 27, 2026 BRISBANE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of advanced strategic therapeut
The Montana-based compounder commits to supporting prescribers and patients in wake of competitor's abrupt exit of California market OSRX, Inc., a leading provider of compounded ophthalmic medications, announced that the company remains fully licensed, fully operational and continues to serve the needs of California ophthalmologists and optometrists, following a significant market shift involving a major competitor. According to a Feb. 2, 2026 company disclosure, ImprimisRx – the compounding division of Harrow (NASDAQ:HROW) – voluntarily forfeited its California license on February 1 and agreed to pay an administrative fine of approximately $157,000 as part of a settlement agreement rea
8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
4 - Accenture plc (0001467373) (Issuer)
4 - Accenture plc (0001467373) (Issuer)
4 - Accenture plc (0001467373) (Issuer)
Matt Prebble to Lead Accenture in UK, Ireland & Africa Accenture (NYSE:ACN) today announced that Shaheen Sayed has been appointed as Chief Commercial Officer of Reinvention Services. In this new role, Shaheen will be responsible for streamlining how Accenture delivers AI-enabled solutions that meet the evolving needs of clients for the AI era. She will play a critical role in integrating capabilities to drive sustainable growth and long-term client value. Shaheen will continue to be a member of the Global Management Committee. She will be succeeded in her role as lead for Accenture in the UK, Ireland & Africa (UKIA) by Matt Prebble, who currently serves as Data & AI lead for EMEA. Matt
Acquisition brings Accenture highly specialized, credentialed talent and enhances industry solutions Accenture (NYSE:ACN) has acquired IAMConcepts, a privately held Canadian company specializing in identity and access management (IAM) services. The acquisition will bolster Accenture's ability to deliver advanced IAM solutions in Canada across key critical infrastructure industries such as financial services, power utilities, mining and transportation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908044917/en/Accenture has acquired IAMConcepts, a privately held Canadian company specializing in identity and access managemen
Accenture (NYSE:ACN) has acquired Superdigital, a U.S.-based social and influencer agency. Superdigital will join Accenture Song to bolster existing client offerings in end-to-end social marketing from audience and community strategy to content, commerce and measurement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250818125462/en/Accenture has acquired Superdigital, a U.S.-based social and influencer agency. Founded in 2013, Superdigital is an award-winning agency known for its highly effective social strategies, community building and content production, particularly across short-form video and platform-native creative. Supe
BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the "Record Date") for the distribution of warrants to purchase Tempest common stock ("Warrants") as a dividend (the "Warrant Dividends"), as contemplated by Tempest's previously announced Asset Purchase Agreement (the "Asset Purchase Agreement") with Erigen LLC and Factor Bioscience Inc. The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of c
Accenture delivers strong new bookings and revenue growth at the top of the company's guided range, with strong profitability and free cash flow; Confirms outlook for fiscal 2026 revenue growth, and adjusted operating margin and EPS Accenture (NYSE:ACN) reported financial results for the first quarter of fiscal 2026 ended November 30, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218755982/en/ All comparisons are to the first quarter of fiscal 2025, unless noted otherwise. Accenture Chair and CEO Julie Sweet "I am very pleased with our $21 billion in new bookings, including 33 clients with quarterly bookings greater t
Accenture Schedules First-Quarter Fiscal 2026 Earnings Call Accenture (NYSE:ACN) will host a conference call at 8:00 a.m. EST on Thursday, December 18, 2025, to discuss its first-quarter fiscal 2026 financial results. An earnings news release will be issued before the call. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202782467/en/ To participate in the teleconference, please dial +1 (877) 883-0383 [+1 (412) 317-6061 outside the U.S., Puerto Rico and Canada] and enter access code 1422495 approximately 15 minutes before the scheduled start of the call. The conference call will also be accessible live via webcast on the Inve
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)